Search

Your search keyword '"Corral de la Fuente, Elena"' showing total 22 results
Start Over Author "Corral de la Fuente, Elena"
22 results on '"Corral de la Fuente, Elena"'

1. MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Author

Garralda, Elena, Beaulieu, Marie-Eve, Moreno, Víctor, Casacuberta-Serra, Sílvia, Martínez-Martín, Sandra, Foradada, Laia, Alonso, Guzman, Massó-Vallés, Daniel, López-Estévez, Sergio, Jauset, Toni, Corral de la Fuente, Elena, Doger, Bernard, Hernández, Tatiana, Perez-Lopez, Raquel, Arqués, Oriol, Castillo Cano, Virginia, Morales, Josefa, Whitfield, Jonathan R., Niewel, Manuela, Soucek, Laura, and Calvo, Emiliano

Published
2024
Full Text
View/download PDF

3. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Author

Joerger, Markus, primary, Calvo, Emiliano, additional, Laubli, Heinz, additional, Lopez, Juanita, additional, Alonso, Guzmán, additional, Corral de la Fuente, Elena, additional, Hess, Dagmar, additional, König, David, additional, Sanchez Perez, Vicky, additional, Bucher, Christoph, additional, Jethwa, Sangeeta, additional, and Garralda, Elena, additional

Published
2023
Full Text
View/download PDF

5. Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report

Author

Pozas, Javier, primary, Albarrán-Fernández, Víctor, additional, González-Campo, Luis, additional, Olmedo-García, María Eugenia, additional, Corral de la Fuente, Elena, additional, Corral-Corral, Iñigo, additional, Carrasco, Ángela, additional, Alonso-Gordoa, Teresa, additional, Molina-Cerrillo, Javier, additional, Lage-Alfranca, Yolanda, additional, Gómez-Rueda, Ana, additional, and Garrido, Pilar, additional

Published
2022
Full Text
View/download PDF

15. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group).

Author

Longo, Federico, primary, Castillo Trujillo, Oscar Alfredo, additional, Serrano Domingo, Juan José, additional, Huertas, Roberto Martin, additional, Corral de la Fuente, Elena, additional, San Juan del Moral, Alberto, additional, Portela, Jaime, additional, Cano, Juana Maria, additional, Reguera Puertas, Pablo, additional, Rodríguez Garrote, Mercedes, additional, Izquierdo Manuel, Marta, additional, Jiménez-Fonseca, Paula, additional, Carrato, Alfredo, additional, and Aranda, Enrique, additional

Published
2019
Full Text
View/download PDF

16. Circulating endothelial cells: Prognostic value in patients with glioblastoma.

Author

Vaz Salgado, María Ángeles, primary, Earl, Julie, additional, Berrocal, Victor Rodriguez, additional, Salge, Freddy, additional, Gomez, Ana, additional, Corral de la Fuente, Elena, additional, Sepulveda Sanchez, Juan Manuel Manuel, additional, Perez-Núñez, Angel, additional, Muriel, Alfonso, additional, Lourido, Daniel, additional, Carrato, Alfredo, additional, and Ley, Luis, additional

Published
2019
Full Text
View/download PDF

17. Impact of adyuvant chemotherapy treatment according to tumor primary location in colorectal cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.

Author

Barquín García, Arantzazu Martínez, primary, Martinez Saez, Olga, additional, Corral de la Fuente, Elena, additional, Serrano Domingo, Juan José, additional, Martín Huertas, Roberto, additional, Villamayor Delgado, Maria, additional, Saavedra Serrano, Cristina, additional, Rodríguez Garrote, Mercedes, additional, Pachón Olmos, Vanesa, additional, Reguera Puertas, Pablo, additional, LONGO, FEDERICO, additional, Guillen, Carmen, additional, Carrato, Alfredo, additional, and Ferreiro, REYES, additional

Published
2018
Full Text
View/download PDF

18. Prognostic relevance of primary tumor location in stage III and II colon cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.

Author

Barquín García, Arantzazu Martínez, primary, Martinez Saez, Olga, additional, Serrano Domingo, Juan José, additional, Martín Huertas, Roberto, additional, Villamayor Delgado, Maria, additional, Saavedra Serrano, Cristina, additional, Corral de la Fuente, Elena, additional, Reguera Puertas, Pablo, additional, LONGO, FEDERICO, additional, Pachón Olmos, Vanesa, additional, Rodríguez Garrote, Mercedes, additional, Guillen, Carmen, additional, Carrato, Alfredo, additional, and Ferreiro, REYES, additional

Published
2018
Full Text
View/download PDF

19. Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant colon cancer: Experience in Ramon y Cajal University Hospital.

Author

Martinez Saez, Olga, primary, Barquín García, Arantzazu Martínez, additional, Villamayor Delgado, Maria, additional, Saavedra Serrano, Cristina, additional, Corral de la Fuente, Elena, additional, Serrano Domingo, Juan José, additional, Martín Huertas, Roberto, additional, Reguera Puertas, Pablo, additional, LONGO, FEDERICO, additional, Pachon, Vanessa, additional, Rodríguez Garrote, Mercedes, additional, Guillen, Carmen, additional, Carrato, Alfredo, additional, and Ferreiro Monteagudo, Reyes, additional

Published
2018
Full Text
View/download PDF

20. Benefit of adjuvant treatment in stages II and III colon cancer: Experience at the Ramón y Cajal University Hospital.

Author

Martinez Saez, Olga, primary, Barquín García, Arantzazu Martínez, additional, Saavedra Serrano, Cristina, additional, Corral de la Fuente, Elena, additional, Serrano Domingo, Juan José, additional, Martín Huertas, Roberto, additional, Villamayor Delgado, Maria, additional, LONGO, FEDERICO, additional, Reguera Puertas, Pablo, additional, Pachon, Vanessa, additional, Rodríguez Garrote, Mercedes, additional, Guillen, Carmen, additional, Carrato, Alfredo, additional, and Ferreiro Monteagudo, Reyes, additional

Published
2018
Full Text
View/download PDF

21. Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response.

Author

Martin Huertas, Roberto, Fernández Abad, María, Corral de la Fuente, Elena, Serrano Domingo, Juan José, and Martínez Jáñez, Noelia

Subjects
MAMMOGRAMS, BREAST surgery, BREAST cancer chemotherapy, THERAPEUTIC use of antimetabolites, ANTIMETABOLITES, BREAST cancer, CANCER relapse, COMBINED modality therapy, GENE expression, HETEROCYCLIC compounds, HISTOLOGY, IMMUNOHISTOCHEMISTRY, INFLAMMATION, EVALUATION of medical care, QUALITY of life, TIME, TRASTUZUMAB, DISEASE remission, DISEASE progression, DUCTAL carcinoma
Abstract

The article discusses early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine. Topics include Trastuzumab was given every three weeks for a complete year; Compared with capecitabine alone, lapatinib in combination with capecitabine increases time to progression (TTP) in patients who have progressed after/on trastuzumab; and lapatinib has shown remarkable activity in IBC in two phase II trials.

Published
2020
Full Text
View/download PDF

22. Analysis of adverse drug events as a way to improve cancer patient care.

Author

Vicente-Oliveros N, Gramage-Caro T, Corral de la Fuente E, Delgado-Silveira E, and Álvarez-Díaz AM

Subjects
Humans, Artificial Intelligence, Patient Care, Quality of Life, Drug-Related Side Effects and Adverse Reactions diagnosis, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions prevention & control, Neoplasms diagnosis, Neoplasms drug therapy, Neoplasms epidemiology
Abstract

Purpose: To define the signals that a new artificial intelligence (AI) system must emit to improve adverse drug events (ADEs) management in oral antineoplastic agents (OAA)., Methods: A multidisciplinary group of experts in patient safety was set up to define what signals the new AI system must emit to improve ADEs management in OAAs. The baseline data for the new AI system were generated through an observational and ambispective study carried out in a university hospital. All patients who met the inclusion criteria were selected consecutively every working day for 6 months. The ADEs were collected by interview and by the review of health records. The ADEs were categorised according to how they could be detected: patient, analysis, examination., Results: The group defined what signals the AI system must emit to improve ADEs management in OAAs: a signal to educate the patient when the possible ADEs were categorised as patient, a signal as a reminder to request a blood test or a microbiological culture when the possible ADEs were categorised as analysis, and a signal as a reminder for the necessity of a clinical examination when the possible ADEs were categorised as examination. A total of 1652 ADEs were reported in the interviews (ADE-interview) with the pharmacist, and doctors noted 1989 ADEs in the health record (ADE-HR). The most frequent ADEs were identified in the patient category., Conclusion: This study opens a new way for better management of ADEs and is the first step in the development of a future technology, which will improve the quality of life of patients., Competing Interests: Competing interests: None declared., (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results